Compare PubMatic Inc (PUBM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs Viatris Inc — how do they compare? PubMatic Inc trades at $12.64 (market cap $600.05M), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Viatris Inc is far larger — about 34.2× PubMatic Inc's market cap, and Viatris Inc pays a 2.73% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals.
| PUBM | VTRS | |
|---|---|---|
Market Cap | $600.05M | $20.50B |
Sector | Technology | Health |
52-Week High | $13.83 | $17.59 |
52-Week Low | $6.28 | $8.74 |
Enterprise Value | $497.55M | $32.71B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PubMatic trades at $12.92, up 1.49% today, with a neutral technical signal and bullish moving averages. The company reported Q1 2026 revenue that beat expectations despite a net loss, and maintains a strong gross margin of 63.22%. Recent news highlights product launches like AgenticOS and partnerships expanding its programmatic advertising reach, with Q2 2026 results due August 6, 2026.
Outlook is mixed: analyst consensus is split evenly between Buy and Hold with a $17.00 price target, suggesting 32% upside, but risks include sustained negative net income margins and competitive pressures in ad tech. Cash flow remains positive, supporting operations amid profitability challenges.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
